The purpose of value-based insurance is to design copays, coinsurance, deductibles and other benefit features that will encourage people to use services that have been demonstrated to be cost-effective, while discouraging use of services for which there is less certain evidence of beneficial effects. These designs have been around long enough now that researchers have examined their effects on both quality and costs. An article in Health Affairs reviews the results of these early studies. (Health Affairs Article) All of the studies focused on prescription drugs, which typically have elaborate copay designs. Thirteen studies were selected, all of which involved copayment reductions on drugs that treated chronic diseases. The studies were all considered to have good to excellent methodological quality. All of the studies showed an improvement in medication adherence after one year, by an average of 3%. Some showed continuing adherence gains beyond one year. The adherence response varied across drug types. Several of the studies examined a potential effect of copay reductions on medical and drug spending. As might be expected, drug spending rose. The effect on overall health spending was less clear, but appeared to be an insignificant change, up or down although some individual studies showed an increase and some a decrease. Two studies looked at utilization and found decreases in ER use, physician visits and hospitalizations. An important future goal of research should be to track overall spending and utilization changes in the long run.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
Research
MedPAC 2019 Report to Congress
June 18, 2019
Headlines
Tags
Access
ACO
Care Management
Chronic Disease
Comparative Effectiveness
Consumer Directed Health
Consumers
Devices
Disease Management
Drugs
EHRs
Elder Care
End-of-Life Care
FDA
Financings
Genomics
Government
Health Care Costs
Health Care Quality
Health Care Reform
Health Insurance
Health Insurance Exchange
HIT
HomeCare
Hospital
Hospital Readmissions
Legislation
M&A
Malpractice
Meaningful Use
Medicaid
Medical Care
Medicare
Medicare Advantage
Mobile
Pay For Performance
Pharmaceutical
Physicians
Providers
Regulation
Repealing Reform
Telehealth
Telemedicine
Wellness and Prevention
Workplace
Related Posts
Commentary
March 28, 2024
More Economic News
The Congressional Budget Office is expressing increasing alarm at the federal deficit and debt situation.
Commentary
March 27, 2024
Funniest Story of the Day
Would would have thought that hail could destroy a solar farm? Certainly not the nut-case…
Commentary
March 27, 2024
What Is Going on in the US Debt Markets?
The Treasury seems determined to rely on massive amounts of short-term debt to finance our…